Electronic Journal of Liver Tumor ›› 2020, Vol. 7 ›› Issue (1): 45-50.
• Review • Previous Articles Next Articles
Received:2019-11-19
Online:2020-03-30
Published:2020-07-17
| [1] Chen W, Zheng R, Baade PD, et al.Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132. [2] 蔡建强,顾晋,秦新裕,等. 中国结直肠癌肝转移诊断和综合治疗指南(2018版)[J]. 中国实用外科杂志, 2018,38(7):707-718. [3] Van cutsem E, Cervantes A, Adaw R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer[J]. Ann Oncol, 2016, 27(8): 1386-1422. [4] Sivesgaard K, Larsen LP, Sorensen M, et al.Diagnostic accuracy of CE-CT, MRI and FDG PET/CT for detecting colorectal cancer liver metastases in patients considered eligible for hepatic resection and /or local ablation[J]. Eur Radiol, 2018, 28(11): 4735-4747. [5] Zech CJ, Korpraphong P, Huppertz A, et al.Randomized multicentre trial of gadoxetic acid-enhanced MRI versus conventional MRI or CT in the staging of colorectal cancer liver metastases[J]. Br J Surg, 2014, 101(6): 613-621. [6] Lencioni R, Della PC, Crocetti L, et al.Clinical management of focal liver lesions: the key role of real-time contrast-enhanced US[J]. Eur Radiol, 2007, 17(Suppl 6): F73-F79. [7] Oba A, Mise Y, Ito H, et al.Clinical implications of disappearing colorectal liver metastases have changed in the era of hepatocyte-specific MRI and contrast-enhanced intraoperative ultrasonography[J]. HPB(Oxford), 2018, 20(8): 708-714. [8] Lu YY, Chen JH, Ding HJ, et al.A systematic review and meta-analysis of pretherapeutic lymph node staging of colorectal cancer by 18F-FDG PET or PET/CT[J]. Nucl Med Commun, 2012, 33(11): 1127-1133. [9] Coenegrachts K, De Geeter F, ter Beek L, et al. Comparison of MRI (including SS SE-EPI and SPIO-enhanced MRI) and FDG-PET/CT for the detection of colorectal liver metastases[J]. Eur Radiol, 2009, 19(2): 370-379. [10] Niekel MC, Bipat S, Stoker J.Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment[J]. Radiology, 2010, 257(3): 674-684. [11] Fennell ML, Das IP, Clauser S, et al.The organization of multidisciplinary care teams: modeling internal and external influences on cancer care quality[J]. J Natl Cancer Inst Monogr, 2010, 40: 72-80. [12] Rabinowitz B.Interdisciplinary breast cancer care: declaring and improving the standard[J]. Oncology(Williston Park), 2004, 18(10): 1263-1275. [13] 韦烨,叶青海,余一祎,等. 多学科团队模式下结直肠癌肝转移的转化性治疗(附86例报告)[J]. 中国实用外科杂志, 2014, 34(9): 862-865. [14] Stevenson HL, Prats MM, Sasatomi E.Chemotherapy-induced Sinusoidal Injury(CSI) score: a novel histologic assessment of chemotherapy-related hepatic sinusoidal injury in patients with colorectal liver metastasis[J]. BMC Cancer, 2017, 17(1): 35. [15] Lochan R, White SA, Manas DM.Liver resection for colorectal liver metastasis[J]. Surg Oncol, 2007, 16(1): 33-45. [16] Pulitano C, Bodingbauer M, Aldrighetti L, et al.Colorectal liver metastasis in the setting of lymph node metastasis: defining the benefit of surgical resection[J]. Ann Surg Oncol, 2012,19(2): 435-442. [17] Chua TC, Saxena A, Liauw W, et al.Hepatectomy and resection of concomitant extrahepatic disease for colorectal liver metastases-a systematic review[J]. Eur J Can (Oxford,England:1990), 2012, 48(12): 1757-1765. [18] 肖永胜,郭磊,叶青海. 结直肠癌肝转移外科治疗[J]. 中华肝脏外科手术学电子杂志, 2019, 8(4): 294-296. [19] 蔡建强. 结直肠癌肝转移诊治进展[J]. 中国临床医生杂志, 2019, 47(8): 886-888. [20] de Jong MC, Pulitano C, Ribero D, et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients[J]. Ann Surg, 2009, 250(3): 440-448. [21] Mise Y, Aloia TA, Brudvik KW, et al.Parenchymal-sparing Hepatectomy in Colorectal Liver Metastasis Improves Salvageability and Survival[J]. Ann Surg, 2016, 263(1): 146-152. [22] Lambert LA, Colacchio TA, Jr BR.Interval hepatic resection of colorectal metastases improves patient selection[J]. Cur Surg, 2000, 135(4): 479-480. [23] Scheele J.Hepatectomy for liver metastases[J]. Brit J Surg, 1993, 80(3): 274-276. [24] De SE, Lassalle FB, Mccormack L, et al.Simultaneous colorectal and hepatic resections for colorectal cancer: postoperative and longterm outcomes[J]. J Amer Coll Surg, 2002, 195(2): 196-202. [25] Martin R, Paty P, Fong Y, et al. Simultaneous liver and colorectal resections are safe for synchronous colorectal liver metastasis[J]. J Amer Coll Surg, 2003, 197 (2), 233-41; discussion 241-242. [26] Chua HK, Sondenaa K, Tsiotos GG, et al.Concurrent vs.Stage colectomy and hepatectomy for primary colorectal cancer with synchronous hepatic metastases[J]. Dis Colon Rectum, 2004, 47(8): 1310-1316. [27] Minagawa M, Yamamoto J, Miwa S, et al.Selection criteria for simultaneous resection in patients with synchronous liver metastasis[J]. Arch Surg, 2006, 141(10): 1006-1012. [28] Lyass S, Zamir G, Matot I, et al.Combined colon and hepatic resection for synchronous colorectal liver metastases[J]. J Surg Oncol, 2001, 78(1): 17-21. [29] Zi Yin, Chao Liu, Yajin Chen, et al.Timing of hepatectomy in resectable synchronous colorectal liver metastases(SCRLM): simultaneous or delayed?[J]. Hepetology, 2013,57(6): 2346-2357. [30] Adam R, de Gramont A, Figueras J, et al. Managing synchronous liver metastases from colorectal cancer: A multidisciplinary international consensus[J]. Cancer Treat Rev, 2015, 41(9) : 729-741. [31] Nordlinger B, Van Cutsem E, Rougier P, et al.Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European colorectal metastases treatment group[J]. Eur J Cancer, 2007, 43(14): 2037-2045. [32] Kulemann V, Schima W, Tamandl D, et al.Preoperative detection of colorectal liver metastases in fatty liver: MDCT or MRI?[J]. Eur J Radiol, 2011, 79(2), e1-6. [33] De Jong MC, van Dam RM, Maas M, et al. The liver-first approach for synchronous colorectal liver metastasis: A 5-year single-centre experience[J]. HPB (Oxford), 2011, 13(10):745-752. [34] Mekenkamp LJ, Koopman M, Teerenstra S, et al.Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs metachronous metastases[J]. Br J Cancer, 2010, 103(2) :159-164. [35] Jegatheeswaran S, Mason JM, Hancock HC, et al.The liver-first approach to the management of colorectal cancer with synchronous hepatic metastases: A systematic review[J]. JAMA Surg, 2013, 148(4): 385-391. [36] Andres A, Toso C, Adam R, et al.A survival analysis of the liver-first reversed management of advanced simultaneous colorectal liver metastases: a Liver Met Survey-based study[J]. Ann Surg, 2012, 256(5): 772-779. [37] Welsh FK, Chandrakumaran K, John TG, et al.Propensity score-matched outcomes analysis of the liver-first approach for synchronous colorectal liver metastases[J]. Br J Surg, 2016, 103(5): 600-606. [38] Imai K, Allard MA, Castro Benitez C, et al.Long-term outcomes of radiofrequency ablation combined with hepatectomy compared with hepatectomy alone for colorectal liver metastases[J]. Br J Surg, 2017, 104(5): 570-579. [39] Ruers T, Punt C, Van coevorden F, et al. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study(EORTC 40004)[J]. Ann Oncol, 2012, 23(10): 2619-2626. [40] Tanis E, Nordlinger B, Mauer M, et al.Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983[J]. Eur J Cancer, 2014, 50(5): 912-919. [41] Solbiati L, Ahmed M, Cova L, et al.Small liver colorectal metastases treated with percutaneous radiofrequency ablation: local response rate and long-term survival with up to 10-year follow-up[J]. Radiology, 2012, 265(3): 958-968. [42] Leung U, Kuk D, D'Angelica MI, et al. Long-term Outcomes Following Microwave Ablation for Liver Malignancies[J]. Brit J Surg, 2015, 102(1): 85-91. [43] Wulf J, Guckenberger M, Haedinger U, et al.Stereotactic radiotherapy of primary liver cancer and hepatic metastases[J]. Acta Oncologica, 2006, 45(7): 838-847. [44] Hoyer M, Roed HHA, Ohlhuis L, et al.Phase II study on stereotactic body radiotherapy of colorectal metastases[J]. Acta Oncologica, 2006, 45(7): 823-830. [45] Aitken KL, Hawkins MA.Stereotactic Body Radiotherapy for Liver Metastases[J]. Clin Oncol, 2015,27(5): 307-315. [46] Fong Y, Fortner J, Sun RL, et al.Clinical score for predicting recurre-nce after hepatic resection for metastatic colorectal cancer:analysis of 1001 consecutive cases[J]. Ann Surg, 1999, 230(3):309-318. [47] Ayez N, Stok EPVD, Grünhagen DJ, et al.The use of neo-adjuvant chemotherapy in patients with resectable colorectal liver metastases: Clinical risk score as possible discriminator[J]. Eur J Surg Oncol, 2015, 41(7): 859-867. [48] Karoui M, Penna C, Amin-Hashem M, et al.Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases[J]. Ann Surg, 2006, 243(1): 1-7. [49] Ruzzenente A, Conci S, Iacono C, et al.Usefulness of contrastenh-anced intraoperative ultrasonography(CE-IOUS) in patients with colorectal liver metastases after preoperative chemotherapy[J]. J Gastrointest Surg, 2013, 17(2): 281-287. [50] Sahani DV, Bajwa MA, Andrabi Y, et al.Current status of imaging and emerging techniques to evaluate liver metastases from colorectalcarcinoma[J]. Ann Surg, 2014, 259(5): 861-872. [51] Yoshita H, Hosokawa A, Ueda A, et al.Predictive value of opti-mal morphologic response to first-line chemotherapy in patients with colorectal liver metastases[J]. Digestion, 2014, 89(1): 43-48. [52] Shindoh J, Loyer EM, Kopetz S, et al.Optimal morphologic response to preoperative chemotherapy: An alternate outcome end point before resection of hepatic colorectal metastases[J]. J Clin Oncol, 2012, 30(36): 4566-4572. |
| No related articles found! |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
